October 10, 2024 02:45 AM GMT M Update Zhejiang Huahai Pharmaceutical Co. Ltd. | Asia Pacific Preliminary 3Q2024 Beat - Reiterate as Top Pick Reaction to earnings Strengthens our investment thesis Modest upside Largely unchanged Impact to our investment thesis Financial results versus consensus Impact to next 12-month consensus EPS Huahai reported a net profit range of Rmb239mn to Rmb297mn (+57% to +95% YoY), which are -3% and 21% versus our estimate. API export and China formulation segments carried the da ...